Last reviewed · How we verify
Nexlizet
Nexlizet is a marketed drug developed by the University of Louisville, with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a competitive advantage due to its patent protection until 2028. The primary risk is the potential loss of exclusivity and increased competition post-patent expiry in 2028.
At a glance
| Generic name | Nexlizet |
|---|---|
| Also known as | bempedoic acid-ezetimibe |
| Sponsor | University of Louisville |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women (PHASE4)
- Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP) (PHASE4)
- Bempedoic Acid Pregnancy Surveillance Program
- Drug Concentrations in Breast Milk and Prediction of Blood Levels of the Breastfed Infants
- Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nexlizet CI brief — competitive landscape report
- Nexlizet updates RSS · CI watch RSS
- University of Louisville portfolio CI